乳腺癌
曲妥珠单抗
帕妥珠单抗
免疫组织化学
免疫系统
医学
肿瘤科
雌激素受体
间质细胞
抗体
内科学
病理
癌症
癌症研究
生物
免疫学
作者
Maeve Hennessy,Ashley Cimino‐Mathews,Jodi M. Carter,Jennifer M. Kachergus,Yaohua Ma,Jeffrey P. Leal,Lilja B. Sólnes,Rita Denbow,Vandana G. Abramson,Lisa A. Carey,Mothaffar F. Rimawi,Jennifer M. Specht,Anna Maria Storniolo,Vicente Valero,Christos Vaklavas,Eric P. Winer,Ian E. Krop,Antonio C. Wolff,Richard L. Wahl,Edith A. Perez
摘要
ER-negative, HER2-positive breast cancer has unique molecular and immunologic features that may predict pCR after neoadjuvant HP. Validation of these potential biomarkers and composite biomarker analyses may guide design of future clinical trials.
科研通智能强力驱动
Strongly Powered by AbleSci AI